Vivo Capital, LLC
"13F equity value" = market value of this filer's US-listed long equity positions only. It excludes cash, bonds, non-US and short positions, so it understates a fund's true assets under management — often by a lot.
13F holdings are disclosed ~45 days after quarter-end, and they never reveal when within the quarter a fund actually bought. So any 13F-based summary is structurally late and blurred — this applies to every fund, including this one.
We backtested copying it anyway. Buying this fund's new positions the day each filing went public, over 21 quarters, returned +18.5% per quarter — versus +4.6% per quarter from simply owning every 13F stock. It beat that baseline in only 61.9% of quarters (excess t = 1.56, not statistically significant). Its filings tell you what it bought — not what you should buy.
Quarterly compounding, invested quarters only · entry 47 days after quarter-end (when 13F data becomes public)
Top 20 holdings of 45 · 2026 Q1
| Ticker | Value | Weight | QoQ |
|---|---|---|---|
| ERAS | $197M | | ADD |
| PRAX | $109M | | ADD |
| TERN | $70M | | TRIM |
| TRVI | $61M | | HOLD |
| DBVT | $56M | | ADD |
| CMPX | $50M | | HOLD |
| TNGX | $45M | | HOLD |
| SABS | $44M | | HOLD |
| CRVS | $41M | | ADD |
| DRUG | $41M | | ADD |
| DNTH | $30M | | HOLD |
| DYN | $28M | | TRIM |
| ABVX | $27M | | TRIM |
| NERV | $26M | | HOLD |
| ACRS | $25M | | TRIM |
| ORIC | $23M | | TRIM |
| ANRO | $23M | | HOLD |
| FTH | $23M | | NEW |
| AVBP | $20M | | NEW |
| LBRX | $20M | | HOLD |
QoQ vs previous quarter's share count · NEW = new position · ADD/TRIM = ±2% shares · HOLD = unchanged.
New positions in 2026 Q1
Method & Limitations
Method: a "new position" = held this quarter, absent last quarter (options excluded; stocks with <50 prior holders excluded to filter spin-off artifacts). Entry 47 days after quarter-end — the first day the public could act on the filing. Benchmark = equal-weighted universe of all 13F-held stocks. Limitations: quarterly snapshots can't see intra-quarter trades; survivorship bias — funds that shut down are absent, which flatters the sample. Statistics, not advice.